1 Introduction (Page No. – 9)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
1.6 Assumptions & Limitations
2 Research Methodology (Page No. -16)
2.1 Introduction
2.2 Secondary Data
2.2.1 Key Data from Secondary Sources
2.3 Primary Data
2.3.1 Breakdown of Primaries
2.3.2 Key Data from Primary Sources
2.3.3 Assumptions
2.4 Market Size Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Market Breakdown and Data Triangulation
3 Executive Summary (Page No. – 29)
3.1 Introduction
3.2 Market Dynamics
3.3 Market Estimation
4 Market Dynamics (Page No. – 34)
4.1 Market Drivers
4.1.1 Rising R&D Investment for Development of Hemophilia Products
4.1.2 Increasing Preference for Prophylactic Treatment
4.1.3 Increasing Number of Diagnosed Hemophilia Patients
4.1.4 Increasing Healthcare Expenditure
4.2 Market Restraints
4.2.1 High Cost of Hemophilia Drugs
4.2.2 Insufficient Reimbursement
4.3 Market Opportunities
4.3.1 Local Partnerships in Pharma-emerging Countries
4.3.2 Rising Disposable Income and Improving Healthcare Infrastructure in Developing Nations
4.3.3 Growing Biosimilar Products Market
4.4 Market Threats
4.4.1 High Entry Barriers Created By Local Government in Certain Countries
4.4.2 Low Switch Rate for Hemophilia Products
4.4.3 High Competition from Established Players
5 Global Bleeding Disorders Treatment Market, By Type (Page No. – 46)
5.1 Introduction
5.2 Hemophilia A
5.3 Hemophilia B
5.4 Von Willebrand Disease (vWD)
5.5 Others
6 Global Bleeding Disorders Treatment Market, By Drug Class (Page No. – 58)
6.1 Introduction
6.2 Plasma Derived Coagulation Factor Concentrates Market
6.3 Global Recombinant Coagulation Factor Concentrate Market
6.4 Global Others Bleeding Disorders Treatment Market
7 Global Bleeding Disorders Treatment Market, By Geography (Page No. – 71)
7.1 Introduction
7.2 North America
7.3 Europe
7.4 Asia-Pacific
7.5 Rest of the World (RoW)
8 Competitive Landscape (Page No. – 101)
8.1 Market Share Analysis, By Key Players
8.2 Key Growth Strategies, 2013 -2016
8.3 Key Growth Strategies: New Product Approval/ Launch, 2013 -2016
8.4 Key Growth Strategies: Agreements, 2013 -2016
8.5 Key Growth Strategies: M&A, 2013 -2016
8.6 Key Growth Strategies: Other Strategies, 2013 -2016
9 Company Profiles (Page No. – 108)
9.1 Baxalta (Now Shire)
9.2 Bayer Pharmaceuticals
9.3 Novo Nordisk A/S
9.4 Pfizer Inc.
9.5 Biogen Idec
9.6 CSL Behring
9.7 Grifols
9.8 Octapharma
10 Appendix (Page No. – 158)
10.1 Key Industry Insights
10.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
10.3 Introducing RT: Real Time Market Intelligence
10.4 Related Reports
Table 1 Pipeline Analysis (Recently Approved)
Table 2 Pipeline Analysis (To Be Approved)
Table 3 Global Bleeding Disorders Treatment Market, By Type, 2014 –2021 (USD Million)
Table 4 Hemophilia A Treatment Market, By Region, 2014 –2021 (USD Million)
Table 5 Hemophilia A Treatment Market, By Disease Management, 2014 –2021 (USD Million)
Table 6 Hemophilia B Treatment Market, By Region, 2014 –2021 (USD Million)
Table 7 Hemophilia B Treatment Market, By Disease Management, 2014 –2021 (USD Million)
Table 8 vWD Treatment Market, By Region, 2014 –2021 (USD Million)
Table 9 Others Treatment Market, By Region, 2014 –2021 (USD Million)
Table 10 Global Hemophilia Treatment Market, By Drug Class, 2014 –2021 (USD Million)
Table 11 Global Plasma Derived Coagulation Factor Concentrate Market, By Class, 2014 –2021 (USD Million)
Table 12 Global Plasma Derived Coagulation Factor Concentrate Market, By Geography, 2014 –2021 (USD Million)
Table 13 Global Recombinant Coagulation Factor Concentrate Market, By Class, 2014 –2021 (USD Million)
Table 14 Global Recombinant Coagulation Factor Concentrate Market, By Geography, 2014 –2021 (USD Million)
Table 15 Other Bleeding Disorders Treatment Market, By Geography, 2014 –2021 (USD Million)
Table 16 Global Market Share, By Region, 2014 -2021 (USD Million)
Table 17 North America: Market Share, By Country, 2014 -2021 (USD Million)
Table 18 North America: Market Share, By Product Type, 2014 -2021 (USD Million)
Table 19 North America: Market Share, By Class, 2014 -2021 (USD Million)
Table 20 North America: Market, By Disease Management, 2014 -2021 (USD Million)
Table 21 Europe: Market Share, By Country,2014 -2021 (USD Million)
Table 22 Europe: Market Share, By Product Type, 2014 -2021 (USD Million)
Table 23 Europe: Market Share, By Class, 2014 -2021 (USD Million)
Table 24 Europe: Market, By Disease Management, 2014 -2021 (USD Million)
Table 25 Asia-Pacific: Market Share, By Country, 2014 -2021 (USD Million)
Table 26 Asia-Pacific Market Share, By Product Type, 2014 -2021 (USD Million)
Table 27 Asia-Pacific: Market Share, By Class, 2014 -2021 (USD Million)
Table 28 Asia-Pacific Market, By Disease Management, 2014 -2021 (USD Million)
Table 29 Row: Market Share, By Country, 2014 -2021 (USD Million)
Table 30 Row: Market Share, By Product Type, 2014 -2021 (USD Million)
Table 31 Row: Market Share, By Class, 2014 -2021 (USD Million)
Table 32 Row: Market, By Disease Management, 2014 -2021 (USD Million)
Table 33 New Product Approval/ Launch, 2013 -2016
Table 34 Agreements, 2013 -2016
Table 35 M&A, 2013 -2016
Table 36 Other Strategies, 2013 -2016
List of Figures (20 Figures)
Fig 1 Global Hemophilia Treatment Market Segmentation
Fig 2 Research Design
Fig 3 Breakdown of Supply-Side Primary Interviews: By Company Type, Designation, Region
Fig 4 Market Size Estimation Diagram
Fig 5 Market Data Triangulation Methodology
Fig 6 Comparative Analysis, Global Market By Type 2015 vs 2021
Fig 7 Comparative Analysis, Global Market By Drug Class 2015 vs 2021
Fig 8 Global Snapshot: Market Scenario, 2015
Fig 9 Impact Analysis: Drivers, Restraints, Opportunities & Challenges
Fig 10 Market: Drivers, Restraints, Opportunities & Challenges
Fig 11 Market Attractiveness, By Type
Fig 12 Market Attractiveness, By Drug Class
Fig 13 Global Market Share, By Region, 2015 (USD Million)
Fig 14 Global Market Scenario, By Geography, 2015
Fig 15 North America: Bleeding Disorders Treatment Market Overview
Fig 16 Europe: Bleeding Disorders Treatment Market Overview
Fig 17 Asia-Pacific: Bleeding Disorders Treatment Market Overview
Fig 18 RoW: Bleeding Disorders Treatment Market Overview
Fig 19 Market Share Analysis, By Key Players, 2015 (%)
Fig 20 Competitive Landscape: Key Developments
【レポートのキーワード】
出血障害、出血障害治療薬、血友病A、血友病B、フォン・ウィルブランド病(vWD)、医薬品、製薬、凝固因子